Resultats globals: 3 registres trobats en 0.01 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
1 p, 257.6 KB Publisher Correction : Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ; Rahmé, Ramy (Université Paris Diderot. Hôpital Saint Louis) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital) ; Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Raffoux, Emmanuel (Université Paris Diderot) ; Tormo, Mar (Universitat de València) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot) ; Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig. Medical Clinic and Policlinic I, Hematology and Cellular Therapy) ; Schlenk, Richard F. (NCT Trial Center, National Center for Tumor Diseases, German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
2021 - 10.1038/s41375-021-01358-3
Leukemia, Vol. 35 (november 2021) , p. 3631  
2.
9 p, 621.5 KB Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study / Kayser, Sabine (Heidelberg University Hospital (Alemanya)) ; Rahmé, Ramy (Université Paris Diderot) ; Martínez-Cuadrón, David (Centro de Investigación Biomédica en Red de Cáncer) ; Ghiaur, Gabriel (Johns Hopkins University) ; Thomas, Xavier (Centre Hospitalier Lyon-Sud. Hospices Civils de Lyon) ; Sobas, Marta (Wroclaw Medical University) ; Guerci-Bresler, Agnes (Nancy University Hospital) ; Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ; Pigneux, Arnaud (Bordeaux University Hospital) ; Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Raffoux, Emmanuel (Université Paris Diderot. Hôpital Saint Louis) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Vey, Norbert (Institut Paoli Calmette) ; de la Serna, Javier (Hospital Universitario 12 de Octubre (Madrid)) ; Salamero, Olga (Hospital Universitari Vall d'Hebron) ; Lengfelder, Eva (University Hospital Mannheim. Department of Hematology and Oncology) ; Levis, Mark (Johns Hopkins University) ; Fenaux, Pierre (Université Paris Diderot. Hôpital Saint Louis) ; Sanz, Miguel A. (Centro de Investigación Biomédica en Red de Cáncer) ; Platzbecker, Uwe (University Hospital Leipzig) ; Schlenk, Richard F. (German Cancer Research Center and Heidelberg University Hospital) ; Adès, Lionel (Université Paris Diderot) ; Montesinos, Pau (Centro de Investigación Biomédica en Red de Cáncer) ; Universitat Autònoma de Barcelona
Data on outcome in older (≥70 years) patients with acute promyelocytic leukemia after treatment with arsenic trioxide (ATO) compared with standard chemotherapy (CTX) is scarce. We evaluated 433 patients (median age, 73. [...]
2020 - 10.1038/s41375-020-0758-4
Leukemia, Vol. 34 (february 2020) , p. 2333-2341  
3.
10 p, 306.7 KB A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-tointermediate risk acute myeloid leukemia : results from a randomized, double-blind, phase 2 tria / Sierra Gil, Jorge (Institut d'Investigació Biomèdica Sant Pau) ; Szer, Jeffrey (Royal Melbourne Hospital (Melbourne, Austràlia)) ; Kassis, Jeannine (Hospital Maisonneuve-Rosemont (Montreal, Canadà)) ; Herrmann, Richard (Royal Perth Hospital (Perth, Austràlia)) ; Lazzarino, Mario (University of Pavia (Itàlia)) ; Thomas, Xavier (Edouard Herriot Hospital (Lyon, França)) ; Noga, Stephen J. (Alvin and Lois Lapidus Cancer Institute (Baltimore, Estats Units d'Amèrica)) ; Baker, Nigel (Biostatistics, Amgen Ltd. (Cambridge, Regne Unit)) ; Dansey, Roger (Clinical Development, Amgen Inc. (Thousand Oaks, Estats Units d'Amèrica)) ; Bosi, Alberto (University of Florence (Itàlia). Department of Critical Care) ; Universitat Autònoma de Barcelona
Background: Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in serious, potentially life-threatening, infection. [...]
2008 - 10.1186/1471-2407-8-195
BMC Cancer, Vol. 8, N. 195 (July 2008) , p. 1-10  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.